Navigating the Waves: Taking a Holistic Approach to Managing Relapsed/Refractory Multiple Myeloma

Overview

Multiple myeloma (MM) remains a challenging hematologic malignancy, with most patients experiencing relapse despite initial treatment success. The management of relapsed/refractory MM (R/R MM) has evolved significantly with the advent of novel therapies, including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and chimeric antigen receptor (CAR) T-cell therapies. However, optimizing treatment for individual patients can be complex and requires a holistic approach. This symposium will explore the healthcare professional and patient views of the prognosis of R/R MM and the factors influencing personalized management strategies. Our panel will discuss different perspectives and approaches, emphasizing the importance of shared decision-making (SDM) in tailoring treatment and how best to improve outcomes and quality of life for this patient population.

IMPORTANT INFORMATION

This symposium will be offered in person and virtually. If you are planning to attend in person or would like to join virtually, you must be a registered attendee of the EHA2025 CONGRESS in order to participate. Please visit the congress website for more details.

Speakers

Joseph Mikhael, MD, MED, FRCPC

Moderator

Professor

Clinical Genomics and Therapeutics

Translational Genomics Research Institute (TGen)

City of Hope Cancer Center

Chief Medical Officer

International Myeloma Foundation

Phoenix, Arizona, United States

Eilidh Duncan, PhD, CPsychol

Panelist

Head of Patient Research

Myeloma Patients Europe

Edinburgh, United Kingdom

Rakesh Popat, MBBS, MRCP, FRCPath, PhD

Panelist

Consultant Haematologist

Associate Professor

University College London Hospital

London, United Kingdom

Jackie Quinn, RN

Panelist

Myeloma Clinical Nurse Specialist

Belfast Trust

Belfast, Northern Ireland,

United Kingdom

Agenda

08:00

Welcome and Introduction: Riding the Tides of Multiple Myeloma

Joseph Mikhael, MD, MED, FRCPC

08:05

Let’s Hear the Physician’s Perspective: Charting the Course in R/R MM Management

Rakesh Popat, MBBS, MRCP, FRCPath, PhD

08:25

Let’s Hear the Patient’s Perspective: Weathering the Storm—Living With R/R MM

Eilidh Duncan

08:40

Let’s Hear the Nurse’s Perspective: Anchoring Patient Care in the MM Journey

Jackie Quinn, RN

08:55

Let’s Collaborate: Building a Lifeline of Holistic Support

All Faculty

09:10

Audience Q&A: Diving Deeper

Joseph Mikhael, MD, MED, FRCPC

09:25

Key Takeaways: Navigating Forward

All Faculty

Piazzale Carlo Magno 1
20149 Milan, Italy
Room: Brown Hall 3

Get Directions

Program Information

Accreditation Statement

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.50 continuing professional development credits (CPD).

Learning Objectives

[bold]Upon completion of this activity, participants will:[/bold] [para]Have increased knowledge regarding the[/para] [list][item]Ways prognosis evolves through cycles of relapse and refractoriness in MM [item]Factors informing the personalized management of R/R MM [/list] [para]Demonstrate greater confidence in their ability to[/para] [list][item]Engage in SDM with their patients for the management of R/R MM [item]Effectively communicate in the care and management of patients with R/R MM [item]Personalize treatment for patients with R/R MM [/list]

Goal Statement

The goal of this activity is for learners to be better able to implement a comprehensive, patient-centered approach to managing R/R MM, incorporating clinical expertise, patient preferences, and multidisciplinary collaboration.

Target Audience

This educational activity is intended for an international audience of hematologists/oncologists and nurses practicing outside the United States and involved in the care of patients with MM.

Supported by an independent educational grant from GSK.